Left ventricular assist device in the presence of subcutaneous implantable cardioverter defibrillator: Data from a multicenter experience
Left ventricular assist devices (LVADs) are an increasingly used strategy for the management of patients with advanced heart failure (HF). Subcutaneous implantable cardioverter defibrillator (S-ICD) might be a viable alternative to conventional ICDs with a lower risk of short- and long-term of devic...
Gespeichert in:
Veröffentlicht in: | International journal of cardiology 2024-04, Vol.400, p.131807-131807, Article 131807 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Left ventricular assist devices (LVADs) are an increasingly used strategy for the management of patients with advanced heart failure (HF). Subcutaneous implantable cardioverter defibrillator (S-ICD) might be a viable alternative to conventional ICDs with a lower risk of short- and long-term of device-related complications and infections.The aim of this multicenter study was to evaluate the outcomes and management of S-ICD recipients who underwent LVAD implantation.
The study population included patients with a preexisting S-ICD who underwent LVAD implantation for advanced HF despite optimal medical therapy.
The study population included 30 patients (25 male; median age 45 [38–52] years).The HeartMate III was the most common LVAD type. Median follow-up in the setting of concomitant use of S-ICDs and LVADs was 7 months (1–20).There were no reports of inability to interrogate S-ICD systems in this population. Electromagnetic interference (EMI) occurred in 21 (70%) patients. The primary sensing vector was the one most significantly involved in determining EMI. Twenty-seven patients (90%) remained eligible for S-ICD implantation with at least one optimal sensing vector. The remaining 3 patients (10%) were ineligible for S-ICD after attempts of reprogramming of sensing vectors. Six patients (20%) experienced inappropriate shocks (IS) due to EMI. Six patients (20%) experienced appropriate shocks. No S-ICD extraction because of need for antitachycardia pacing, ineffective therapy or infection was reported.
Concomitant use of LVAD and S-ICD is feasible in most patients. However, the potential risk of EMI oversensing, IS and undersensing in the post-operative period following LVAD implantation should be considered. Careful screening for EMI should be performed in all sensing vectors after LVAD implantation.
•Subcutaneous implantable cardioverter defibrillator (S-ICD) is effective in terminating ventricular arrythmias•Electromagnetic interference is common in left ventricular assist device (LVAD) patients leading to inappropriate shocks•10% of LVAD patients are ineligible for S-ICD after attempts of reprogramming of sensing vectors•Deactivation of the antitachycardia therapy of the S-ICD before LVAD implantation should be considered•Before reactivation of the device, all sensing vectors should be evaluated with respect to adequate sensing. |
---|---|
ISSN: | 0167-5273 1874-1754 |
DOI: | 10.1016/j.ijcard.2024.131807 |